{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:38:20Z","timestamp":1793191100599,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s12325-024-02999-3","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T09:52:10Z","timestamp":1729849930000},"page":"4557-4580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Fluticasone Furoate\/Umeclidinium\/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3646-7828","authenticated-orcid":false,"given":"David","family":"Mannino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2988-5684","authenticated-orcid":false,"given":"Kristi","family":"DiRocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4525-7673","authenticated-orcid":false,"given":"Guillaume","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2601-6214","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5936-5579","authenticated-orcid":false,"given":"Stephen G.","family":"Noorduyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Urosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7151-4311","authenticated-orcid":false,"given":"Rosirene","family":"Paczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"2999_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/resp.12660","volume":"21","author":"JL L\u00f3pez-Campos","year":"2016","unstructured":"L\u00f3pez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21:14\u201323.","journal-title":"Respirology"},{"key":"2999_CR2","unstructured":"American Lung Association. COPD Trends Brief: Burden. https:\/\/www.lung.org\/research\/trends-in-lung-disease\/copd-trends-brief\/copd-burden#:~:text=The%20medical%20cost%20of%20COPD%20is%20%2424.0%20billion,room%20costs%2C%20and%20%24800%20million%20in%20outpatient%20costs. Accessed 22 May\u00a02024."},{"key":"2999_CR3","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.15585\/mmwr.mm7246a1","volume":"72","author":"Y Liu","year":"2023","unstructured":"Liu Y, Carlson SA, Watson KB, Xu F, Greenlund KJ. Trends in the prevalence of chronic obstructive pulmonary disease among adults aged \u2265 18\u00a0years - United States, 2011\u20132021. MMWR Morb Mortal Wkly Rep. 2023;72:1250\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2999_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101228","volume":"9","author":"F Blasi","year":"2014","unstructured":"Blasi F, Cesana G, Conti S, et al. The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS ONE. 2014;9:e101228.","journal-title":"PLoS ONE"},{"key":"2999_CR5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.rmed.2010.09.003","volume":"105","author":"AA Dalal","year":"2011","unstructured":"Dalal AA, Shah M, D\u2019Souza AO, Rane P. Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med. 2011;105:454\u201360.","journal-title":"Respir Med"},{"key":"2999_CR6","doi-asserted-by":"publisher","first-page":"P21","DOI":"10.1164\/rccm.19811P21","volume":"198","author":"S Lareau","year":"2018","unstructured":"Lareau S, Moseson E, Slatore CG. Exacerbation of COPD. Am J Respir Crit Care Med. 2018;198:P21\u20132.","journal-title":"Am J Respir Crit Care Med"},{"key":"2999_CR7","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2024 report. https:\/\/goldcopd.org\/wp-content\/uploads\/2024\/02\/GOLD-2024_v1.2-11Jan24_WMV.pdf Accessed 10 Mar 2024."},{"key":"2999_CR8","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/thorax.57.10.847","volume":"57","author":"GC Donaldson","year":"2002","unstructured":"Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847\u201352.","journal-title":"Thorax"},{"key":"2999_CR9","volume":"3","author":"S Fortis","year":"2021","unstructured":"Fortis S, Wan ES, Kunisaki K, et al. Increased mortality associated with frequent exacerbations in COPD patients with mild-to-moderate lung function impairment, and smokers with normal spirometry. Respir Med: X. 2021;3:100025.","journal-title":"Respir Med: X"},{"key":"2999_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1183\/13993003.01391-2014","volume":"47","author":"S Hartl","year":"2016","unstructured":"Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit. Eur Respir J. 2016;47:113\u201321.","journal-title":"Eur Respir J"},{"key":"2999_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/ajhp\/zxz306","volume":"77","author":"SG Bollmeier","year":"2020","unstructured":"Bollmeier SG, Hartmann AP. Management of chronic obstructive pulmonary disease: a review focusing on exacerbations. Am J Health-Syst Pharm. 2020;77:259\u201368.","journal-title":"Am J Health Syst Pharm"},{"key":"2999_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2147\/COPD.S234942","volume":"15","author":"I Iheanacho","year":"2020","unstructured":"Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:439\u201360.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2999_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.107090","volume":"206","author":"H Ruan","year":"2023","unstructured":"Ruan H, Zhang H, Wang J, Zhao H, Han W, Li J. Readmission rate for acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med. 2023;206:107090.","journal-title":"Respir Med"},{"key":"2999_CR14","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.rmed.2004.02.013","volume":"98","author":"JB Oostenbrink","year":"2004","unstructured":"Oostenbrink JB, Rutten-van M\u00f6lken MP. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med. 2004;98:883\u201391.","journal-title":"Respir Med"},{"key":"2999_CR15","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/resp.12642","volume":"20","author":"NA Negewo","year":"2015","unstructured":"Negewo NA, Gibson PG, McDonald VM. COPD and its comorbidities: impact, measurement and mechanisms. Respirology. 2015;20:1160\u201371.","journal-title":"Respirology"},{"key":"2999_CR16","unstructured":"GSK press release. Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US; September 18, 2017. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/trelegy-ellipta-approved-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-appropriate-patients-with-copd-in-the-us\/. Accessed 10 Mar 2024."},{"key":"2999_CR17","unstructured":"National Committee for Quality Assurance. Medicare special needs plans performance results: HEDIS 2016. https:\/\/www.cms.gov\/Medicare\/Health-Plans\/SpecialNeedsPlans\/Downloads\/2016-HEDIS-Report.pdf. Accessed 10 Mar 2024."},{"key":"2999_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105938","volume":"166","author":"CF Vogelmeier","year":"2020","unstructured":"Vogelmeier CF, Rom\u00e1n-Rodr\u00edguez M, Singh D, Han MK, Rodr\u00edguez-Roisin R, Ferguson GT. Goals of COPD treatment: focus on symptoms and exacerbations. Respir Med. 2020;166:105938.","journal-title":"Respir Med"},{"key":"2999_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12890-022-01892-5","volume":"22","author":"J O'Toole","year":"2022","unstructured":"O\u2019Toole J, Krishnan M, Riekert K, Eakin MN. Understanding barriers to and strategies for medication adherence in COPD: a qualitative study. BMC Pulm Med. 2022;22:98.","journal-title":"BMC Pulm Med"},{"key":"2999_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2147\/COPD.S337668","volume":"17","author":"D Mannino","year":"2022","unstructured":"Mannino D, Bogart M, Germain G, et al. Benefit of prompt versus delayed use of single-inhaler fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) following a COPD exacerbation. Int J Chron Obstruct Pulmon Dis. 2022;17:491\u2013504.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2999_CR21","unstructured":"US Bureau of Labor Statistics. Consumer price index. https:\/\/www.bls.gov\/cpi\/factsheets\/medical-care.htm. Accessed 11 Mar 2024."},{"key":"2999_CR22","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/pds.1673","volume":"17","author":"PC Austin","year":"2008","unstructured":"Austin PC. Goodness-of-fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score. Pharmacoepidemiol Drug Saf. 2008;17:1202\u201317.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2999_CR23","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130\u20139.","journal-title":"Med Care"},{"key":"2999_CR24","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.clinthera.2007.10.006","volume":"29","author":"NA Hanania","year":"2007","unstructured":"Hanania NA. Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes. Clin Ther. 2007;29:2121\u201333.","journal-title":"Clin Ther"},{"key":"2999_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/15412555.2016.1199669","volume":"14","author":"C Jinjuvadia","year":"2017","unstructured":"Jinjuvadia C, Jinjuvadia R, Mandapakala C, Durairajan N, Liangpunsakul S, Soubani AO. Trends in outcomes, financial burden, and mortality for acute exacerbation of chronic obstructive pulmonary disease (COPD) in the United States from 2002 to 2010. COPD. 2017;14:72\u20139.","journal-title":"COPD"},{"key":"2999_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2147\/COPD.S378867","volume":"18","author":"NA Hanania","year":"2023","unstructured":"Hanania NA, Bunner SH, Bengtson LGS, Ismaila AS, Bogart M. COPD exacerbations, costs, and health care resource utilization before and after initiation of fluticasone furoate\/umeclidinium\/vilanterol in routine care in the USA. Int J Chron Obstruct Pulmon Dis. 2023;18:407\u201318.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2999_CR27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1513\/AnnalsATS.201909-672OC","volume":"17","author":"LC Myers","year":"2020","unstructured":"Myers LC, Faridi MK, Hasegawa K, Hanania NA, Camargo CA Jr. The Hospital Readmissions Reduction Program and readmissions for chronic obstructive pulmonary disease, 2006\u20132015. Ann Am Thorac Soc. 2020;17:450\u20136.","journal-title":"Ann Am Thorac Soc"},{"key":"2999_CR28","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.2147\/COPD.S419119","volume":"18","author":"A Czira","year":"2023","unstructured":"Czira A, Akiyama S, Ishii T, et al. Benefit of prompt vs delayed initiation of triple therapy following an exacerbation in patients with COPD in Japan: a retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2023;18:2933\u201353.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2999_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12931-023-02523-1","volume":"24","author":"AS Ismaila","year":"2023","unstructured":"Ismaila AS, Rothnie KJ, Wood RP, et al. Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF\/UMEC\/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study. Respir Res. 2023;24:229.","journal-title":"Respir Res"},{"key":"2999_CR30","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.2147\/COPD.S370540","volume":"17","author":"DMG Halpin","year":"2022","unstructured":"Halpin DMG, Rothnie KJ, Banks V, et al. Comparative adherence and persistence of single- and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in an English real-world primary care setting. Int J Chron Obstruct Pulmon Dis. 2022;17:2417\u201329.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2999_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106807","volume":"197","author":"D Mannino","year":"2022","unstructured":"Mannino D, Bogart M, Wu B, et al. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: a real-world study. Respir Med. 2022;197:106807.","journal-title":"Respir Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02999-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02999-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02999-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T08:12:32Z","timestamp":1731139952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02999-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2999"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02999-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"20 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David Mannino is a consultant for AstraZeneca, the COPD Foundation, Genentech, GSK, Regeneron, and Up-to-Date. David Mannino is also an expert witness on behalf of people suing the tobacco and vaping industries. Kristi DiRocco, Stephen G. Noorduyn, and Rosirene Paczkowski are employed by GSK and\/or hold financial equities in GSK. Stephen G. Noorduyn is also a\u00a0PhD candidate at McMaster University. Guillaume Germain and Fran\u00e7ois Lalibert\u00e9 are employees of Groupe d\u2019analyse, Lt\u00e9e, which received funding from GSK to conduct this study. Ana Urosevic was an employee of Groupe d\u2019analyse, Lt\u00e9e, at the time of the study. Current affiliation details for Ana Urosevic: Thumbtack, San Francisco, CA, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As this was an analysis of claims data, institutional review board (IRB) approval was not required. Per Title 45 of the Code of Federal Regulations, Part 46 (), the administrative claims data analysis of our study was exempt from the IRB review as it was a retrospective analysis of existing data (hence no patient intervention or interaction), and no patient-identifiable information was included in the claims dataset.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}